Clint Behrend, MD
Gastroenterology · Idaho Falls, IDNPI 1538138243
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 245 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 31 manufacturers reported payments, led by AbbVie at 41.2% of the total.
Across 245 payments — averaging $16.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$309
- Bristol Myers Squibb$250
- Johnson & Johnson$237
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$180
- Sanofi$104
- plus $1K from 25 others
Across 143 payments — averaging $5790.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$417K
- Takeda Pharmaceuticals U.S.A., Inc.$133K
- Genentech, Inc.$82K
- Janssen Research & Development, LLC$66K
- AbbVie$54K
- F. Hoffmann-la Roche AG$35K
- plus $42K from 2 others
What the payments were for
- Food & beverage$3,978100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 116 | $1,638 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $309 |
| Bristol Myers Squibb | 13 | $250 |
| Johnson & Johnson | 13 | $237 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $180 |
| Sanofi | 6 | $104 |
| Regeneron Healthcare Solutions, Inc. | 6 | $102 |
| Ferring Pharmaceuticals Inc. | 6 | $91 |
| Boston Scientific | 4 | $90 |
| Gilead | 5 | $89 |
| Madrigal Pharmaceuticals | 3 | $87 |
| Intercept Pharmaceuticals, Inc. | 4 | $81 |
| Aimmune Therapeutics, Inc. | 4 | $80 |
| Pfizer | 5 | $75 |
| Medtronic | 3 | $66 |
| Ardelyx, Inc. | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 5 | $56 |
| QOL Medical, LLC | 3 | $51 |
| Nestle Healthcare Nutrition Inc. | 2 | $45 |
| Shield Therapeutics Inc | 2 | $39 |
| Merck | 2 | $33 |
| Fresenius Kabi USA, LLC | 2 | $27 |
| Celltrion USA Inc. | 1 | $26 |
| Tersera Therapeutics LLC | 1 | $25 |
| Shire North American Group Inc | 1 | $23 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Orphalan Inc | 1 | $18 |
| Braintree Laboratories, Inc. | 1 | $18 |
| Sandoz | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
How this compares
$3,978 in reported general payments places this provider in the 80th percentile of 70 gastroenterology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ZenpepLipase/Protease/Amylase | 16 | $40,462 |
| Mesalamine | 34 | $18,508 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 237 | $15,637 |
| Budesonide DrBudesonide | 40 | $15,427 |
| VoqueznaVonoprazan Fumarate | 23 | $14,034 |
| LinzessLinaclotide | 20 | $11,154 |
| Famotidine | 576 | $8,008 |
| Sucralfate | 179 | $7,277 |
| Colestipol Hcl | 119 | $7,180 |
| Omeprazole | 533 | $5,106 |
| Dexlansoprazole DrDexlansoprazole | 16 | $4,192 |
| Ursodiol | 31 | $4,161 |
| Lubiprostone | 26 | $3,990 |
| Metoclopramide Hcl | 184 | $2,193 |
| Mycophenolate Mofetil | 25 | $2,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aimmune Therapeutics, Inc.Zenpep | $80 | $40,46216 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $56 | $14,03423 claims |
| AbbVieLinzess | $1,638 | $11,15420 claims |
| Braintree Laboratories, Inc.Sutab | $18 | $1,77911 claims |
| SandozLansoprazole | $18 | $1,26630 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 70 gastroenterology providers in Idaho.
Other gastroenterology in Idaho Falls
- Todd WilliamsIdaho Falls$8K
- Larry EvansIdaho Falls$7K
- Ned WarnerIdaho Falls$7K
- Michael RichinsIdaho Falls$6K
- Paul HendrixIdaho Falls$2K
- Jacob WendlingIdaho Falls$421
- David JohnsonCoeur D Alene$190K
- Matthew SericatiBoise$111K
- Ashley EvansBoise$69K
- Bryan BrimhallBoise$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.